- Home
- BUD vs BMY Comparison
BUD vs BMY Comparison
Compare BUD & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUD
- BMY
- Stock Information
- Founded
- BUD 1366
- BMY 1887
- Country
- BUD Belgium
- BMY United States
- Employees
- BUD N/A
- BMY N/A
- Industry
- BUD Beverages (Production/Distribution)
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- BUD Consumer Staples
- BMY Health Care
- Exchange
- BUD Nasdaq
- BMY Nasdaq
- Market Cap
- BUD 121.4B
- BMY 120.5B
- IPO Year
- BUD N/A
- BMY N/A
- Fundamental
- Price
- BUD $62.10
- BMY $59.59
- Analyst Decision
- BUD Buy
- BMY Hold
- Analyst Count
- BUD 3
- BMY 14
- Target Price
- BUD $64.00
- BMY $58.00
- AVG Volume (30 Days)
- BUD 2.2M
- BMY 12.2M
- Earning Date
- BUD 05-07-2025
- BMY 04-24-2025
- Dividend Yield
- BUD 1.69%
- BMY 4.16%
- EPS Growth
- BUD 10.00
- BMY N/A
- EPS
- BUD 2.86
- BMY N/A
- Revenue
- BUD $59,768,000,000.00
- BMY $48,300,000,000.00
- Revenue This Year
- BUD $1.64
- BMY N/A
- Revenue Next Year
- BUD $4.53
- BMY N/A
- P/E Ratio
- BUD $21.71
- BMY N/A
- Revenue Growth
- BUD 0.65
- BMY 7.32
- 52 Week Low
- BUD $45.94
- BMY $39.35
- 52 Week High
- BUD $67.49
- BMY $63.33
- Technical
- Relative Strength Index (RSI)
- BUD 62.90
- BMY 50.17
- Support Level
- BUD $61.13
- BMY $58.23
- Resistance Level
- BUD $62.75
- BMY $61.64
- Average True Range (ATR)
- BUD 0.64
- BMY 1.45
- MACD
- BUD -0.49
- BMY -0.16
- Stochastic Oscillator
- BUD 39.27
- BMY 39.74
About BUD Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. The company's portfolio contains six of the top 10 beer brands by volume, according to Euromonitor, and we estimate it distributes 23 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev, an 87% stake in Budweiser APAC, and in 2016 it acquired SABMiller.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.